We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
Read MoreHide Full Article
Key Takeaways
Halozyme raised 2026 revenue guidance to $1.86B-$1.925B as third-quarter royalties jumped 44% to $341M.
OCREVUS ZUNOVO, OPDIVO Qvantig and RYBREVANT FASPRO are growing royalty contributors for Halozyme.
A Dutch court found Halozyme's EP622 patent infringed, restricting KEYTRUDA Qlex in eight European markets.
Halozyme Therapeutics, Inc. (HALO - Free Report) raised its 2026 outlook after stronger royalty contributions from established therapies and newer subcutaneous launches. Management also emphasized partner expansion and progress toward the next generation of drug-delivery products.
The third-quarter earnings call put longer-term royalty durability, clinical milestones and the patent dispute with Merck at the center of investors' attention.
Halozyme Raises Its Full-Year Outlook
Chief financial officer Darren Snellgrove raised 2026 revenue guidance to $1.86-$1.925 billion and royalty guidance to $1.235-$1.255 billion, citing stronger partner-product demand.
Adjusted EBITDA guidance rose to $1.24-$1.29 billion, and non-GAAP earnings per share guidance to $8.75-$9.05. The expected adjusted EBITDA margin remained approximately 67%.
Quarterly revenues grew 39% to $493 million, above the Zacks Consensus Estimate of $482 million. Non-GAAP earnings per share reached $2.39, beating the $2.29 estimate. Royalty revenues climbed 44% to $341 million.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Chief executive officer Helen Torley identified OCREVUS ZUNOVO, OPDIVO Qvantig and RYBREVANT FASPRO as growing royalty contributors alongside established products.
Roche reported that global OCREVUS conversion to subcutaneous exceeded 20%. Bristol Myers Squibb reported 17% conversion of its OPDIVO IV business, with an eventual conversion expectation of 30-40%.
During questioning, Torley emphasized further conversion potential and expanding VYVGART Hytrulo indications that broaden eligible patient populations.
Halozyme Expands Its ENHANZE Pipeline
Torley said that argenx, Incyte and Johnson & Johnson expanded existing ENHANZE collaborations, adding four target nominations. Argenx now has eight exclusive targets covered by its agreement.
Pfizer, Incyte and argenx advanced separate ENHANZE-enabled programs into Phase I development. Halozyme has 12 clinical-stage programs and expects 13 by year-end, with GSK planning a subcutaneous belantamab study.
To a TD Cowen analyst, Torley said that up to 13 new molecular entities could launch from 2029 to 2032, subject to development progress, excluding new indications for marketed products.
HALO Prepares Hypercon for Clinical Testing
Torley reaffirmed that two Hypercon-partnered products are expected to enter Phase I studies in the first half of 2027, supported by clinical supplies scheduled for the first quarter.
Responding to Leerink Partners, she said that scale-up was progressing toward clinical production. She told Evercore ISI that the projected $1 billion Hypercon royalty opportunity involves five to seven products, mostly established therapies.
Asked by TD Cowen about Hypercon economics, Torley emphasized collaboration payments and milestone revenues rather than enzyme sales. Aerocon is targeted for clinical entry in the second half of 2028.
Halozyme Details Its Merck Patent Position
Torley emphasized an October Dutch court decision finding infringement of Halozyme's European EP622 patent and restricting KEYTRUDA Qlex in eight European markets. A separate injunction already applies in Germany.
To Leerink Partners, Torley distinguished the European patent from U.S. patents, where Merck had won initial validity rulings. She said appeals could run into 2028.
Asked by Morgan Stanley about U.S. supply, Torley declined to assess Merck's global supply chain. Halozyme believes the order affects European manufacturing arrangements and has sued an Italian manufacturer.
HALO Maintains Financial Discipline
Snellgrove prioritized ENHANZE, Hypercon and Aerocon investments alongside balance-sheet management. Halozyme ended September with $1.08 billion in cash and marketable securities and 2.4 times net leverage.
Halozyme repurchased $400 million in shares during 2026 and issued $1.5 billion of convertible notes. Management plans to address the 2027 and 2028 notes at maturity.
To Citizens JMP, Snellgrove said acquisitions must complement existing technologies, extend royalties or strengthen the long-term outlook while meeting return requirements.
Halozyme Keeps Its Focus on Future Royalties
Management's message centered on adding royalty streams through existing partners, clinical development and complementary delivery technologies, while protecting intellectual property.
Snellgrove said that the company plans to provide 2027 guidance and refresh its long-range outlook with fourth-quarter results in February.
Zacks Rank and Style Scores Offer Context
HALO carries a Zacks Rank #3 (Hold) at present, indicating a neutral near-term earnings-revision signal. Its Growth Score of A points to favorable growth characteristics, while the Momentum Score of B reflects a relatively favorable reading. It carries a Value Score of C. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock also has a VGM Score of A, indicating a strong combined value, growth and momentum profile. These scores complement rather than replace the Zacks Rank, which can change as analysts revise estimates following the reported results.
View the Zacks #1 Rank List
Image: Bigstock
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
Key Takeaways
Halozyme Therapeutics, Inc. (HALO - Free Report) raised its 2026 outlook after stronger royalty contributions from established therapies and newer subcutaneous launches. Management also emphasized partner expansion and progress toward the next generation of drug-delivery products.
The third-quarter earnings call put longer-term royalty durability, clinical milestones and the patent dispute with Merck at the center of investors' attention.
Halozyme Raises Its Full-Year Outlook
Chief financial officer Darren Snellgrove raised 2026 revenue guidance to $1.86-$1.925 billion and royalty guidance to $1.235-$1.255 billion, citing stronger partner-product demand.
Adjusted EBITDA guidance rose to $1.24-$1.29 billion, and non-GAAP earnings per share guidance to $8.75-$9.05. The expected adjusted EBITDA margin remained approximately 67%.
Quarterly revenues grew 39% to $493 million, above the Zacks Consensus Estimate of $482 million. Non-GAAP earnings per share reached $2.39, beating the $2.29 estimate. Royalty revenues climbed 44% to $341 million.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Halozyme Therapeutics, Inc. price-consensus-eps-surprise-chart | Halozyme Therapeutics, Inc. Quote
HALO Points to New Royalty Contributors
Chief executive officer Helen Torley identified OCREVUS ZUNOVO, OPDIVO Qvantig and RYBREVANT FASPRO as growing royalty contributors alongside established products.
Roche reported that global OCREVUS conversion to subcutaneous exceeded 20%. Bristol Myers Squibb reported 17% conversion of its OPDIVO IV business, with an eventual conversion expectation of 30-40%.
During questioning, Torley emphasized further conversion potential and expanding VYVGART Hytrulo indications that broaden eligible patient populations.
Halozyme Expands Its ENHANZE Pipeline
Torley said that argenx, Incyte and Johnson & Johnson expanded existing ENHANZE collaborations, adding four target nominations. Argenx now has eight exclusive targets covered by its agreement.
Pfizer, Incyte and argenx advanced separate ENHANZE-enabled programs into Phase I development. Halozyme has 12 clinical-stage programs and expects 13 by year-end, with GSK planning a subcutaneous belantamab study.
To a TD Cowen analyst, Torley said that up to 13 new molecular entities could launch from 2029 to 2032, subject to development progress, excluding new indications for marketed products.
HALO Prepares Hypercon for Clinical Testing
Torley reaffirmed that two Hypercon-partnered products are expected to enter Phase I studies in the first half of 2027, supported by clinical supplies scheduled for the first quarter.
Responding to Leerink Partners, she said that scale-up was progressing toward clinical production. She told Evercore ISI that the projected $1 billion Hypercon royalty opportunity involves five to seven products, mostly established therapies.
Asked by TD Cowen about Hypercon economics, Torley emphasized collaboration payments and milestone revenues rather than enzyme sales. Aerocon is targeted for clinical entry in the second half of 2028.
Halozyme Details Its Merck Patent Position
Torley emphasized an October Dutch court decision finding infringement of Halozyme's European EP622 patent and restricting KEYTRUDA Qlex in eight European markets. A separate injunction already applies in Germany.
To Leerink Partners, Torley distinguished the European patent from U.S. patents, where Merck had won initial validity rulings. She said appeals could run into 2028.
Asked by Morgan Stanley about U.S. supply, Torley declined to assess Merck's global supply chain. Halozyme believes the order affects European manufacturing arrangements and has sued an Italian manufacturer.
HALO Maintains Financial Discipline
Snellgrove prioritized ENHANZE, Hypercon and Aerocon investments alongside balance-sheet management. Halozyme ended September with $1.08 billion in cash and marketable securities and 2.4 times net leverage.
Halozyme repurchased $400 million in shares during 2026 and issued $1.5 billion of convertible notes. Management plans to address the 2027 and 2028 notes at maturity.
To Citizens JMP, Snellgrove said acquisitions must complement existing technologies, extend royalties or strengthen the long-term outlook while meeting return requirements.
Halozyme Keeps Its Focus on Future Royalties
Management's message centered on adding royalty streams through existing partners, clinical development and complementary delivery technologies, while protecting intellectual property.
Snellgrove said that the company plans to provide 2027 guidance and refresh its long-range outlook with fourth-quarter results in February.
Zacks Rank and Style Scores Offer Context
HALO carries a Zacks Rank #3 (Hold) at present, indicating a neutral near-term earnings-revision signal. Its Growth Score of A points to favorable growth characteristics, while the Momentum Score of B reflects a relatively favorable reading. It carries a Value Score of C. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock also has a VGM Score of A, indicating a strong combined value, growth and momentum profile. These scores complement rather than replace the Zacks Rank, which can change as analysts revise estimates following the reported results.